Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos has initiated Phase 2A study evaluating the safety and efficacy of GLPG0974 in patients with mild to moderate ulcerative colitis.
Subscribe to our email newsletter
Patients will be randomised in 2:1 ratio with either 200mg of GLPG0974 two times each day or placebo for a period of four weeks.
The recruitment will be carried out in multiple sites across four countries including Belgium, Latvia, Czech Republic and Slovakia.
Galapagos CSO Piet Wigerinck said GLPG0974 was developed as a drug to inhibit FFA2 that plays a vital role in inflammatory diseases.
"GLPG0974 is the first FFA2 antagonist being evaluated clinically, and we are looking forward to the results in ulcerative colitis patients. If the drug shows efficacy in these patients, this will be an important step, as there is currently no cure for this disease. We expect to report the results of the study in early 2014," Wigerinck added.
The study is designed to assess efficacy, effects on selected biomarkers, safety and tolerability and pharmacokinetics of the candidate.
Results of the double-blind, placebo-controlled study are expected in 2014.